Cound this be ? and yet maybe is will.....
Zaktualizowano
CRISPR Therapeutics - the next Trillion Dollar Company.
November 14, 2024
Investing ins SpaceX before it goes Public.... This is good advice !!! Space is the new War Economy, I mead the defense machine needs a new business line, and space is more profitable than any war economy X 50 - war economy today 34 Trillion Annually according to my calculations.
Space realignment, so much more - the 1st massive breakthrough will be in biotech, breakthrough, I mean extremely profitable manufacturing will be in bio-manufacturing of parts for transplant, oh yeah. it is coming.
In the meantime read my posts on Crispr Therapeutics.
Truly Amazing times. Go to my profile and sort for posts, all three some 10 - describing the founders winning the Nobel Price for Chemistry, their first products being approved by the FDA and expanding revenue, the pipeline, and lastly an NPV Valuations of $1,075 per share today.... that is coming, kid you not.
This is the collection of post I made about CRISPR THERAPEUTICS - It discusses all the positives about this stock. The positives are truly overwhelming in quantity, in speed of development, in how this company will upgrade life itself, from humans to nature, prepare for a quantum leap. Even terraforming Mars, it is all in the cards for CIRSPR Therapeutics, ticker CrSp, traded in USA Markets. Oh, before I forget, these posts also discuss the acceleration of development of new therapies, because of AI.
CRISPR THERAPEUTICS is expected to greatly accelerate discoveries and implementation of therapies
The integration of AI with CRISPR technology is poised to revolutionize medicine by enabling precise, effective, and personalized therapies. AI enhances the CRISPR genome editing process by optimizing guide RNA design, predicting outcomes, and minimizing off-target effects, leading to safer and more efficient treatments for diseases such as sickle cell anemia and cancer.
Transformation Timeline
• Short-Term (1-3 years): Expect advancements in existing therapies, with AI improving the precision of CRISPR applications in clinical settings.
• Medium-Term (3-5 years): Introduction of tailored gene therapies based on individual genetic profiles, leveraging AI for real-time data analysis.
• Long-Term (5+ years): A shift towards a new paradigm of medicine where AI-driven CRISPR technologies dominate, making chemical-based processes seem outdated.
The synergy between AI and CRISPR is expected to accelerate the development of next-generation therapies, transforming healthcare into a more personalized and effective approach “CRISPR Therapeutics Shares Hold Strong Potential: The Calculated NPV Surpasses $1,073!”
CRISPR Therapeutics commercializes its FDA-approved therapies primarily through strategic partnerships, particularly with Vertex Pharmaceuticals. Here’s how the commercialization process works:
Commercialization Strategy
1. Partnership with Vertex Pharmaceuticals:
• Vertex leads the global development, manufacturing, and commercialization of CTX001 (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta-thalassemia.
• Under their agreement, Vertex is responsible for 60% of program costs and profits, while CRISPR retains 40% .
2. Revenue Structure:
• CRISPR received a $900 million upfront payment from Vertex, with potential milestone payments of up to $200 million upon regulatory approval .
• CRISPR also benefits from royalties on future sales of CTX001 and other products developed under this partnership.
3. Regulatory Approvals:
• CRISPR has successfully submitted Biologics License Applications (BLAs) for exa-cel, which have received priority review from the FDA, enhancing the speed of commercialization .
4. Market Access and Distribution:
• The collaboration allows CRISPR to leverage Vertex’s established infrastructure for market access and distribution, ensuring that therapies reach patients effectively.
Future Commercialization Efforts
• CRISPR is also advancing its pipeline of therapies in various stages of clinical trials, including CAR T-cell therapies like CTX110 and CTX131, which are expected to follow a similar commercialization strategy through partnerships or independent efforts once they receive regulatory approval .
This collaborative approach maximizes CRISPR’s resources while allowing it to focus on innovation and development in gene editing technologies. Crispr therapeutics (CRSP)
Currently Approved Therapies
1. Casgevy (exagamglogene autotemcel): Approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
2. Zolgensma (onasemnogene abeparvovec-xioi): Gene therapy for spinal muscular atrophy.
3. Kymriah (tisagenlecleucel): CAR T-cell therapy for certain types of leukemia and lymphoma.
4. Yescarta (axicabtagene ciloleucel): CAR T-cell therapy for large B-cell lymphoma.
5. Luxturna (voretigene neparvovec-rzyl): Gene therapy for inherited retinal disease.
Pending Approval Therapies
1. CTX001 (exagamglogene autotemcel):
• Indications: Sickle cell disease and transfusion-dependent beta thalassemia.
• Estimated Approval Dates:
• SCD: December 8, 2023 (FDA)
• TDT: March 30, 2024 (FDA)
2. CTX110: Allogeneic CAR T-cell therapy targeting CD19.
• Estimated Approval Date: TBD, currently in Phase 2 trials.
3. CTX131: Allogeneic CAR T-cell therapy targeting CD70.
• Estimated Approval Date: TBD, currently in Phase 1 trials.
4. CTX310 and CTX320: Targeting lipoprotein(a) for cardiovascular diseases.
• Estimated Clinical Entry: First half of 2024.
These therapies represent significant advancements in gene editing and cellular therapies, with CTX001 being particularly notable as the first CRISPR-based therapy expected to gain FDA approval
CRSP TICKER SYMBOL - To arrive at a theoretical share value for CRISPR Therapeutics (CRSP), we can use the projected future revenues and the company’s market capitalization.
Current Market Data
• Current Share Price: $51.62
• Market Capitalization: Approximately $4.4 billion
Revenue Projections
Using the speculative revenue projections:
• 2024: $4 billion
• 2028: $7.1 billion
• 2030: $9.5 billion
• 2034: $17.8 billion
Valuation Method
Assuming a price-to-sales (P/S) ratio of 18.93 (as per current data) for future revenue projections, we can estimate the theoretical share value.
Theoretical Share Value Calculation
1. Projected Revenue for 2028: $7.1 billion
2. Estimated Market Cap in 2028:
3. Shares Outstanding: Approximately 85 million .
4. Theoretical Share Value in 2028:
Discounting to Present Value
To find the present value of this share price using a discount rate of 10% over 4 years (from 2024 to 2028):
Conclusion
The theoretical present share value of CRISPR Therapeutics today could be approximately $1,073, based on speculative future revenues and current market conditions. This projection assumes successful commercialization of their therapies and sustained growth in the gene editing market
The CRISPR THERAPIITICS market is projected to grow significantly, with estimates suggesting it will reach approximately $17.8 billion by 2034, up from $3.4 billion in 2023, reflecting a compound annual growth rate (CAGR) of 16.1% from 2024 to 2034.
Speculative Revenue Projections
• 2024: $4 billion
• 2028: $7.1 billion
• 2030: $9.5 billion (based on a CAGR of 15.6% from 2023)
• 2034: $17.8 billion
Present Value Calculation
Using a discount rate of 10%, the present value (PV) of future cash flows can be estimated as follows:
Where is the discount rate and is the number of years until the cash flow occurs.
Summary
The total present value of projected revenues from CRISPR initiatives could amount to approximately $19.67 billion, indicating a significant potential return on investment in this rapidly evolving market
November 14, 2024
Investing ins SpaceX before it goes Public.... This is good advice !!! Space is the new War Economy, I mead the defense machine needs a new business line, and space is more profitable than any war economy X 50 - war economy today 34 Trillion Annually according to my calculations.
Space realignment, so much more - the 1st massive breakthrough will be in biotech, breakthrough, I mean extremely profitable manufacturing will be in bio-manufacturing of parts for transplant, oh yeah. it is coming.
In the meantime read my posts on Crispr Therapeutics.
Truly Amazing times. Go to my profile and sort for posts, all three some 10 - describing the founders winning the Nobel Price for Chemistry, their first products being approved by the FDA and expanding revenue, the pipeline, and lastly an NPV Valuations of $1,075 per share today.... that is coming, kid you not.
This is the collection of post I made about CRISPR THERAPEUTICS - It discusses all the positives about this stock. The positives are truly overwhelming in quantity, in speed of development, in how this company will upgrade life itself, from humans to nature, prepare for a quantum leap. Even terraforming Mars, it is all in the cards for CIRSPR Therapeutics, ticker CrSp, traded in USA Markets. Oh, before I forget, these posts also discuss the acceleration of development of new therapies, because of AI.
CRISPR THERAPEUTICS is expected to greatly accelerate discoveries and implementation of therapies
The integration of AI with CRISPR technology is poised to revolutionize medicine by enabling precise, effective, and personalized therapies. AI enhances the CRISPR genome editing process by optimizing guide RNA design, predicting outcomes, and minimizing off-target effects, leading to safer and more efficient treatments for diseases such as sickle cell anemia and cancer.
Transformation Timeline
• Short-Term (1-3 years): Expect advancements in existing therapies, with AI improving the precision of CRISPR applications in clinical settings.
• Medium-Term (3-5 years): Introduction of tailored gene therapies based on individual genetic profiles, leveraging AI for real-time data analysis.
• Long-Term (5+ years): A shift towards a new paradigm of medicine where AI-driven CRISPR technologies dominate, making chemical-based processes seem outdated.
The synergy between AI and CRISPR is expected to accelerate the development of next-generation therapies, transforming healthcare into a more personalized and effective approach “CRISPR Therapeutics Shares Hold Strong Potential: The Calculated NPV Surpasses $1,073!”
CRISPR Therapeutics commercializes its FDA-approved therapies primarily through strategic partnerships, particularly with Vertex Pharmaceuticals. Here’s how the commercialization process works:
Commercialization Strategy
1. Partnership with Vertex Pharmaceuticals:
• Vertex leads the global development, manufacturing, and commercialization of CTX001 (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta-thalassemia.
• Under their agreement, Vertex is responsible for 60% of program costs and profits, while CRISPR retains 40% .
2. Revenue Structure:
• CRISPR received a $900 million upfront payment from Vertex, with potential milestone payments of up to $200 million upon regulatory approval .
• CRISPR also benefits from royalties on future sales of CTX001 and other products developed under this partnership.
3. Regulatory Approvals:
• CRISPR has successfully submitted Biologics License Applications (BLAs) for exa-cel, which have received priority review from the FDA, enhancing the speed of commercialization .
4. Market Access and Distribution:
• The collaboration allows CRISPR to leverage Vertex’s established infrastructure for market access and distribution, ensuring that therapies reach patients effectively.
Future Commercialization Efforts
• CRISPR is also advancing its pipeline of therapies in various stages of clinical trials, including CAR T-cell therapies like CTX110 and CTX131, which are expected to follow a similar commercialization strategy through partnerships or independent efforts once they receive regulatory approval .
This collaborative approach maximizes CRISPR’s resources while allowing it to focus on innovation and development in gene editing technologies. Crispr therapeutics (CRSP)
Currently Approved Therapies
1. Casgevy (exagamglogene autotemcel): Approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
2. Zolgensma (onasemnogene abeparvovec-xioi): Gene therapy for spinal muscular atrophy.
3. Kymriah (tisagenlecleucel): CAR T-cell therapy for certain types of leukemia and lymphoma.
4. Yescarta (axicabtagene ciloleucel): CAR T-cell therapy for large B-cell lymphoma.
5. Luxturna (voretigene neparvovec-rzyl): Gene therapy for inherited retinal disease.
Pending Approval Therapies
1. CTX001 (exagamglogene autotemcel):
• Indications: Sickle cell disease and transfusion-dependent beta thalassemia.
• Estimated Approval Dates:
• SCD: December 8, 2023 (FDA)
• TDT: March 30, 2024 (FDA)
2. CTX110: Allogeneic CAR T-cell therapy targeting CD19.
• Estimated Approval Date: TBD, currently in Phase 2 trials.
3. CTX131: Allogeneic CAR T-cell therapy targeting CD70.
• Estimated Approval Date: TBD, currently in Phase 1 trials.
4. CTX310 and CTX320: Targeting lipoprotein(a) for cardiovascular diseases.
• Estimated Clinical Entry: First half of 2024.
These therapies represent significant advancements in gene editing and cellular therapies, with CTX001 being particularly notable as the first CRISPR-based therapy expected to gain FDA approval
CRSP TICKER SYMBOL - To arrive at a theoretical share value for CRISPR Therapeutics (CRSP), we can use the projected future revenues and the company’s market capitalization.
Current Market Data
• Current Share Price: $51.62
• Market Capitalization: Approximately $4.4 billion
Revenue Projections
Using the speculative revenue projections:
• 2024: $4 billion
• 2028: $7.1 billion
• 2030: $9.5 billion
• 2034: $17.8 billion
Valuation Method
Assuming a price-to-sales (P/S) ratio of 18.93 (as per current data) for future revenue projections, we can estimate the theoretical share value.
Theoretical Share Value Calculation
1. Projected Revenue for 2028: $7.1 billion
2. Estimated Market Cap in 2028:
3. Shares Outstanding: Approximately 85 million .
4. Theoretical Share Value in 2028:
Discounting to Present Value
To find the present value of this share price using a discount rate of 10% over 4 years (from 2024 to 2028):
Conclusion
The theoretical present share value of CRISPR Therapeutics today could be approximately $1,073, based on speculative future revenues and current market conditions. This projection assumes successful commercialization of their therapies and sustained growth in the gene editing market
The CRISPR THERAPIITICS market is projected to grow significantly, with estimates suggesting it will reach approximately $17.8 billion by 2034, up from $3.4 billion in 2023, reflecting a compound annual growth rate (CAGR) of 16.1% from 2024 to 2034.
Speculative Revenue Projections
• 2024: $4 billion
• 2028: $7.1 billion
• 2030: $9.5 billion (based on a CAGR of 15.6% from 2023)
• 2034: $17.8 billion
Present Value Calculation
Using a discount rate of 10%, the present value (PV) of future cash flows can be estimated as follows:
Where is the discount rate and is the number of years until the cash flow occurs.
Summary
The total present value of projected revenues from CRISPR initiatives could amount to approximately $19.67 billion, indicating a significant potential return on investment in this rapidly evolving market
Zlecenie aktywne
Uwaga
This company is the real deal. In the Biotech sector, it’s common to see a wave of imitators popping up as soon as a successful company emerges, often led by fraudsters looking to cash in quickly. But CRISPR Therapeutics stands apart. Founded by a Nobel Prize winner in Biochemistry, with backing from Harvard and significant Swiss funding, they are not just talk. They’ve begun selling approved therapies, and more are on the horizon.
This is an incredible opportunity. Getting in now could mean setting up your kids for a future where they’re not just millionaires but potentially trillionaires. The story is unfolding, and the revenue is already starting to flow in. Wink Wink
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.